Sector News

FTC requests additional info from Boston Scientific and BTG ahead of $4.2B merger

February 15, 2019
Life sciences

The Federal Trade Commission is requesting additional information from Boston Scientific and BTG ahead of their proposed $4.2 billion acquisition deal.

The antitrust regulator is seeking additional documentation related to the companies’ therapeutic beads businesses—which form the bulk of BTG’s interventional oncology offerings, and which Boston Scientific has eyed as the means to help transform its cancer franchise, from one primarily offering delivery tools into a $500 million enterprise.

BTG’s TheraSphere Y-90 radiotherapy for liver cancer, for example, consists of implantable glass microspheres that deliver high doses of localized radiation. It’s currently in early-stage development for lung and breast cancers, as well as bone metastases.

The London-based medtech company also offers its LC Bead line of hydrogel microspheres, which are used to block the flow of blood and starve growing hypervascular tumors and arteriovenous malformations, as well as a chemotherapy-eluting bead system.

Following its announcement last November, analysts at Jeffries described BTG’s interventional medicine and oncology portfolios as the “hidden gem” in the deal—and that it could be as transformative as Boston Scientific’s 2015 acquisition of AMS, which helped the medtech giant enter the men’s health and urology sectors.

In addition, more than 90% of BTG’s current revenue comes from the U.S., which Boston Scientific sees as an opportunity to pull new products up through its global marketing and commercialization teams and into new markets.

In a statement, Boston Scientific and BTG said they plan to cooperate with the FTC’s request as soon as possible, and believe they are still on track with their previous timeline for the closure of the deal, expected by mid-2019. They also noted the planned merger has already received sign-offs from regulatory authorities in Germany and Taiwan.

And while the transaction has been unanimously approved by the boards of directors of both companies, the deal is still subject to a vote of BTG’s shareholders, scheduled for Feb. 28. BTG’s three largest shareholders, covering about a third of the company’s outstanding shares, have already committed to vote in favor of the deal.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach